Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poly-ICLC in recurrent pediatric low-grade gliomas
NCT01188096Phase 2Completed
- Sponsor
- Wake Forest University Health Sciences
- Start
- Aug 2010
- Primary completion
- Jul 2019
- Modality
- Antisense DNA, Small Interfering RNA (siRNA), MicroRNA (miRNA)
- Countries
- 1
01
Overview
A Phase 2 trial of poly iclc in glioma, sponsored by Wake Forest University Health Sciences. Started Aug 2010; status: completed.
02
Drugs
poly iclc
03
Conditions
glioma
Beyond the preview
Go deeper on NCT01188096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01188096.